glp 1 agonist eli lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Lilly's Triple Agonist Retatrutide Holds

Mobile IV services: Mobile providers often lack medical supervision and use standardized formulations rather than customized dosing

GHK-Cu (Gly-His-Lys-Cu2+)

As an integrative hub of neuroendocrine, immune, and metabolic signaling, the MGBA has garnered substantial attention for its potential role in the core symptoms of ASDincluding social deficits and language impairmentswith important clinical implications

Tirzepatide users were less likely to experience any major cardiovascular problems following surgery than people not on the drug (roughly 30% lower risk), though the rate of some problems like heart attacks remained roughly the same between the two groups

patients in this analysis were likely not affected by the CVS formulary change

cant wait to see my results in another month